|| List of recent Proteins-related patents
|Detection of conformationally altered proteins|
The invention provides methods and kits for detecting conformationally altered proteins and prions in a sample. In one embodiment, the conformationally altered proteins and prions are associated with amyloidogenic diseases..
|Blid; a novel protein domain for interaction with the bcl-2 family of proteins|
In this invention, a novel protein interaction domain is provided along with several of its variants. This domain is involved in protein-protein interactions with the bcl-2 family of proteins.
|Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry|
Disclosed here is a method for measuring the kinetics (i.e., the molecular flux rates—synthesis and breakdown or removal rates) of a plurality of proteins or organic metabolites in living systems. The methods may be accomplished in a high-throughput, large-scale automated manner, by using existing mass spectrometric profiling techniques and art well known in the fields of static proteomics and static organeomics, without the need for additional biochemical preparative steps or analytic/instrumental devices..
The Regents Of The University Of California
|Method of detection of amino acid sequence and/or identification of peptides and proteins, by use of a new derivatization reagent and synthesis of 5-formyl-benzene-1,3-disulphonic acid as derivatization reagent|
Present invention refers to a novel and improved method of derivatization and detection of amino acid sequence and/or identification of proteins, peptides by a new derivatization compound. Precisely, the method discloses a novel approach to derivatization of peptides or proteins by compounds comprising two or more sulfonyl groups and analysis of derivatized analytes in negative mode of operation of mass spectrometer.
|Methods and compositions employing secreted proteins that reflect autophagy dynamics within tumor cells|
A diagnostic reagent or device for determining the autophagy levels of cancer cells comprises a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying a biomarker selected from il-8, il-1β, dkk-3, fam-3c and/or lif, or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. Another reagent contains ligands to two or more of these biomarkers.
The Trustees Of The University Of Pennsylvania
|Apparatus and methods for low temperature small angle x-ray scattering|
Apparatus and methods for performing small angle x-ray scattering (saxs) at low (cryogenic) temperatures for determining the structure of and changes in the structure of proteins, dna, rna, and other biological molecules and biomolecular assemblies and structures. A cryogenic, small angle x-ray scattering (saxs) application sample holder, includes a sample cell including a base portion and at least two parallel walls disposed on the base, wherein the sample cell has a liquid volume capacity defined by the walls and the base portion of 0.001 to 10 microliters.
|Brassica plant comprising mutant fatty acyl-acp thioesterase alleles|
The invention relates to crop plants comprising novel seed lipid compositions. Provided are both wild type and mutant nucleic acid molecules encoding brassica fatty acyl-acyl carrier protein (acp) thioesterase b proteins (fatb) and the proteins as such.
Bayer Cropscience N.v.
|Transgenic plants with enhanced agronomic traits|
This invention provides transgenic plant cells with recombinant dna for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil.
Monsanto Technology Llc
|Method for the manufacturing of recombinant proteins harbouring an n-terminal lysine|
This invention relates to a novel method for manufacturing and obtaining recombinant proteins, such as clostridial neurotoxins, harbouring an n-terminal lysine from precursor proteins. The method comprises the step of expressing a nucleic acid sequence encoding a precursor protein comprising an n-terminal motif, which can be recognised by an endoprotease specific for a lysine in p′1 position, and the step of cleaving the precursor protein with the endoprotease.
Merz Pharma Gmbh & Co. Kgaa
|Hybrid proteins and uses thereof|
There are disclosed hybrid proteins comprising at least one signal sequence; at least one dna binding domain; and at least one cell penetrating peptide (cpp) domain. In embodiments the cpp domain is a tat domain, and the dna binding domain is a hu domain.
Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
The present invention relates to amino acid sequences and nanobodies that are directed against epidermal growth factor receptor 2 (her2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.. .
Cd3 binding polypeptides
The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with cd3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scfvs, fabs, di-scfvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments.
Emergent Product Development Seattle Llc
Dual variable domain immunoglobulins and uses thereof
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.. .
Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble fibroblast growth factor receptor 1 (fgfr1) fusion protein such as an extracellular domain of an fgfr1 polypeptide linked to an fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight.
Five Prime Therapeutics, Inc.
Analysis of ubiquitnated polypeptides
The disclosure relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them.
Cell Signaling Technology, Inc.
Methods and compositions for detecting, imaging, and treating small cell lung cancer utilizing post-translationally modified residues and higher molecular weight antigenic complexes in proteins
The present invention discloses ectopically expressed isoaspartylated proteins and antigenic peptide fragments thereof as potential biomarkers for cancer such as small cell lung cancer. Also disclosed are antigen recognition agents capable of specifically recognizing and binding to isoaspartylated proteins and/or antigenic peptide fragments thereof.
University Of Southern California
High affinity tcr proteins and methods
T cell receptors (tcrs) that have higher affinity for a ligand than wild type tcrs are provided. These high affinity tcrs are formed by mutagenizing a t cell receptor protein coding sequence to generate a variegated population of mutants of the t cell receptor protein coding sequence; transforming the t cell receptor mutant coding sequence into yeast cells; inducing expression of the t cell receptor mutant coding sequence on the surface of yeast cells; and selecting those cells expressing t cell receptor mutants that have higher affinity for the peptide/mhc ligand than the wild type t cell receptor protein.
The Board Of Trustees Of The University Of Illinois
Charged nutritive fragments, proteins and methods
Charged nutritive proteins provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/l at ph 7.
Mutant apoprotein of photoprotein with low calcium sensitivity
Calcium-binding photoproteins showing the luminescence pattern with a slow decay of are desired. The invention provides a mutant apoprotein comprising an amino acid sequence wherein the 23rd to 34th amino acids in the amino acid sequence of seq id no: 2 are substituted with an amino acid represented by formula i below: xaa23-xaa24-xaa25-xaa26-xaa27-xaa28-xaa29-xaa30-xaa31-xaa32-xaa33-xaa 34; having a function to bind to the peroxide of coelenterazine or the peroxide of a coelenterazine analogue to form a photoprotein capable of emitting light under the action of calcium ions; and, having a half decay time of the luminescence emitted by binding of the photoprotein to calcium ions being not less than 2 seconds..
Treatment of microbial infections
The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal mscramm or mscramm-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy..
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe
Flagellin fusion proteins
Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion. The protein portion includes at least a portion of a globular head, and at least a portion of at least one secondary structure having at least one β-sheet at a bottom of the globular head that causes the globular head to essentially retain its tertiary structure.
Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated apc proteins, an immortalized human colonic epithelial cell (hcec) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.. .
Dual phase column membrane protein micro-reactor and use thereof
The present invention relates to a biphasic microreactor for membrane proteins pretreatment comprising cation exchange and anion exchange materials packed in sequence in a container as stationary phase, where membrane proteins capture, ph adjustment, reduction, alkylation and tryptic digestion processed in situ. Thus the microreactor has advantages of high recovery, ease of operation, high efficiency and high throughput..
Dalian Institute Of Chemical Physics, Chinese Academy Of Sciences
Therapeutic composition with a botulinum neurotoxin
The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin..
Merz Pharma Gmbh & Co. Kgaa
Fibronectin based scaffold domain proteins that bind to myostatin
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company
Variant activin receptor polypeptides and uses thereof
The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (hsp) preparation or an α-2-macroglobulin (α2m) preparation with a non-vaccine treatment modality. In particular, an hsp preparation or an α2m preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases.
University Of Connecticut Health Center
Nylon-3 co-polymers and synthetic lung surfactant compositions containing same
Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins b and c (sp-b and sp-c), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of sp-b and sp-c has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes.
Wisconsin Alumni Research Foundation
Dietary compositions comprising capsules obtained by coacervation without the use of toxic cross-linking agents
Method for preparing double-walled capsules includes: a) dispersing a lipophilic active principle in an aqueous solution containing at least one anionic and at least one cationic polymer; b) adjusting the ph so that the positive charges of the cationic polymer balance the negative charges of the anionic polymer to induce coacervation; c) adsorbing resulting coacervate droplets on the surface of the active principle to form capsules; d) introducing a solution of anionic polymers into the reaction medium obtained in step (c); e) introducing the resulting mixture into a unit forming drops; f) mixing the resulting drops with a solution of divalent salts and forming the double-walled capsules. The method uses no cross-linking agents and the nutritional active principle is selected from among bioactive lipids, salts of trace elements, liposoluble vitamins, prebiotics, probiotics, proteins and/or concentrates of milk proteins, vegetable or animal enzymes, peptides and amino acids, sugars, flavour enhancers..
Societe D'exploitation De Produits Pur Les Industries Chimiques Seppic
Harvest operations for recombinant proteins
The present invention contemplates methods of producing a recombinant protein comprising fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, harvesting said recombinant protein under conditions where do2 levels are greater than 0%, purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable dhna-recombinant protein adduct, as measured by an iec assay at 310 nm. Furthermore, method of producing a recombinant protein comprising fermenting a mene gene-deleted prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, harvesting said recombinant protein, purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable dhna-recombinant protein adduct, as measured by an iec assay at 310 nm, wherein the recombinant protein yield is increased by about 20% or greater is contemplated..
Vectors for delivery of light sensitive proteins and methods of use
Provided herein are compositions and methods for gene and etiology-nonspecific and circuit-specific treatment of diseases, utilizing vectors for delivery of light-sensitive proteins to diseased and normal cells and tissues of interest.. .
University Of Florida Research Foundation, Inc.
Strong constitutive promoters for heterologous expression of proteins in plants
Nucleic acid promoters isolated from panicum virgatum capable of transcriptional activation of heterologous nucleic acids are provided. Constructs, vectors and transgenic plants that include nucleic acid promoters are described.
Methods and compositions for synthesis of nucleic acid molecules using multiplerecognition sites
The present invention provides compositions and methods for recombinational cloning. The compositions include vectors having multiple recombination sites and/or multiple topoisomerase recognition sites.
Life Technologies Corporation
Alteration and modulation of protein activity by varying post-translational modification
Embodiments of the invention include methods of altering the enzymatic activity or solubility of an extremophilic enzyme or post-translationally modifying a protein of interest via using isolated or partially purified glycosyltransferases and/or post-translational modification proteins, extracts of cells comprising glycosyltransferases and/or post-translational modification proteins, and/or in cells comprising one or more glycosyltransferases and/or post-translational modification proteins.. .
Battelle Energy Alliance, Llc
Novel coelenterazine compounds and methods of use
Calcium reacting photoproteins are a class of self-illuminating proteins that emit light upon contact with calcium. Fluorescent proteins are small proteins that change the color of light when excited.
Molecularly imprinted polymers
The present invention refers to new classes of polymerisable monomers targeting biotin, a biotin derivative, a biotin analogue or a biotinylated molecule and related structures, as well as molecularly imprinted polymers obtainable by polymerisation of at least one of these monomers and at least one cross-linking monomer in the presence of a suitable template molecule. The obtained polymers may be used for separation of biotin and related small molecules, together with larger biotinylated molecules of biological origin, e.g.
The University Of Kent
Hydrogel made of a chemically modified polysaccharide-protein blend, the production of a ppb hydrogel, and uses thereof
According to the invention, a hydrogel comprising chemically modified polysaccharides and proteins is provided. Furthermore, a method is provided in order to produce a hydrogel from mixtures of polysaccharides and proteins.
Construction Research & Technology Gmbh
Fluorescent and colored proteins and methods for using them
The field of this invention relates to methods for combining genetic elements such that the activity of one of the elements provides a means for identifying, enriching, selecting for, or enhancing the activity of a second element. The invention also includes specific elements and combinations of elements..
Dna Twopointo, Inc.
Novel far red fluorescent protein
The present invention relates to a nucleic acid molecule encoding a polypeptide having a fluorescence emission activity at a wavelength of at least 630 nm, wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule encoding a polypeptide having the amino acid sequence of seq id no: 1; (b) a nucleic acid molecule encoding a polypeptide having the amino acid sequence of seq id no: 1, with the exception that in the polypeptide of seq id no: 1 (b-i) glutamic acid at the position corresponding to position 16 is replaced by glycine; (b-ii) asparagine at the position corresponding to position 125 is replaced by aspartic acid; and/or (b-iii) lysine at the position corresponding to position 185 is replaced by asparagine; (c) a nucleic acid molecule encoding a polypeptide having at least 94% sequence identity to the polypeptide encoded by the nucleic acid molecule of (a) or (b); (d) a nucleic acid molecule having the nucleotide sequence of seq id no: 2; (e) a nucleic acid molecule having the nucleotide sequence of seq id no: 2, with the exception that said nucleic acid molecule has (e-i) at the positions corresponding to positions 48 to 50 of seq id no: 2 a nucleotide triplet selected from the group consisting of ggt, ggc, gga and ggg; or (e-ii) at the positions corresponding to positions 375 to 377 of seq id no: 2 a nucleotide triplet selected from the group consisting of gat and gac; and/or (e-iii) at the positions corresponding to positions 555 to 557 of seq id no: 2 a nucleotide triplet selected from the group consisting of aat and aac; (f) a nucleic acid molecule having the nucleotide sequence of (d), (e) or (f), wherein each thymine is replaced by uracile; and (g) a nucleic acid molecule degenerate with respect to the nucleic acid molecule of (d) or (e). The present invention further relates to a vector comprising the nucleic acid molecule of the invention and a non-human host transformed with the vector of the invention.
Helmholtz Zentrum München - Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh
New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
The present invention concerns new modular base-per-base specific nucleic acid binding domains (mbbbd) derived from newly identified proteins from the bacterial endosymbiont burkholderia rhizoxinica and their use for engineering nucleic acid processing enzymes, such as specific endonucleases or transcription activators.. .
Thiol-selective water-soluble polymer derivatives
The present invention provides water-soluble, polymer derivatives having a thiol-selective terminus suitable for selective coupling to thiol groups, such as those contained in the cysteine residues of proteins.. .
Engineered anthrax lethal toxin for targeted delivery
The present invention provides methods and systems for targeted delivery of a compound to a target cell that overexpresses two different proteinases. Specifically, two different modified protective antigen proteins, each comprising a cleavage site recognized by a distinct proteinase in place of the native proteinase cleavage site recognized by furin, are administered in combination with a compound that contains a protective antigen binding site.
The United States Of America As Represented By The Sec. Of The Dept. Of Health And Human Services
Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions.
Oxthera Intellectual Property Ab
Composition capable of improving stability of bacteriophage lysin proteins
The present invention relates to a composition for improving the stability of bacteriophage originated lysin proteins greatly even when the composition contains the bacteriophage originated lysin proteins at a high concentration. More precisely, the present invention relates to a method and a composition for improving significantly the stability of sal-1 or lysk, the bacteriophage originated lysin protein, included at a high concentration in the composition..
Itron Biotechnology, Inc.
Composition with increased bioavailability of orally administered embryo-peptides and process for its obtainment
The invention refers to a composition standardized in heterologous embryo-peptides, used as a dietary supplement and to a process for its obtainment. The composition consists of heterologous embryonic extract, standardized in embryo-peptides, maltodextrin, selenium yeast, chromium yeast, zinc chelated in embryo-peptides, pyridoxine, mixture of cationic peptides, formed by enzymatic hydrolysis of vitellus and egg white remaining after chicken embryo harvesting, with antitrypsin and endocytosis promoting activity, sodium taurocholate, expanded silicon dioxide, magnesium stearate, methylparaben and propylparaben.
Sc Hipocrate 2002 Serv Srl
Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and/or salt thereof for improving liver functioning
A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.
System for and converting agricultural waste to animal feed and other valuable raw materials
Methods of and devices for extracting nutrients (such as, proteins, oils, hydrocarbons, antioxidants, organic antibiotics, minerals, and vitamins) from discarded plant wastes (roots, skins, seeds, stalks, leaves, and stems) using grinding and separation processes are provided.. .
Lee Tech Llc
Inferring biological pathways from unstructured text analysis
A biological pathway is a series of actions that take place in an organism that lead to some resulting pathology or otherwise change the organism state. In the cell, these actions typically take place between molecules called proteins.
International Business Machines Corporation
Integrated quantification protein measurements in clinical proteomics
Methods are provided for determining the expression level of target proteins in a subject. A plurality of respective peptide transitions are generated from a plurality of proteins obtained from a biological sample from the subject, wherein the plurality of proteins comprises both target and normalizing proteins.
Integrated Diagnostics, Inc.
Plant promoters and uses thereof
The invention concerns tools, methods and compositions for modifying plants and/or protein expression in plants. The invention concerns in particular transcriptional promoters enabling specific expression in the trichomes, constructs containing said promoters, and their uses for genetically modifying cells, seeds or plants.
Philip Morris Products S.a.
Screening polynucleotide libraries for variants that encode functional proteins
The present invention provides methods based on screening expressed polynucleotide libraries for soluble proteins.. .
Method for producing hypoallergenic peanut products
A peanut food product with reduced levels of allergenic proteins such as ala h1/h2/h3 is produced by initiating the germination process in raw peanuts, holding the peanuts in moist conditions to initiate germination, and then treating with bromelain.. .
Molecular Epidemiology Inc.
Cd27l antigen binding proteins
The present invention relates to cd27l antigen binding proteins, such an antibodies, polynucleotides encoding said cd27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with cd27l expression.. .
Fn14 binding proteins and uses thereof
The present disclosure provides proteins comprising antibody antigen binding domains that bind to fn14 and uses thereof. The present disclosure also provides methods for treating wasting disorders, such as cachexia..
Amyloid-beta binding proteins
The present invention relates to amyloid-beta (aβ) binding proteins. Antibodies of the invention have high affinity to aβ(20-42) globulomer or any aβ form that comprises the globulomer epitope.
Interleukin-2 fusion proteins and uses thereof
The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (il-2). More particularly, the invention concerns fusion proteins of immunoglobulins and mutant il-2 that exhibit improved properties for use as therapeutic agents, e.g.
Hoffman-la Roche Inc.
Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity
The invention provides a method for obtaining a broadly neutralizing antibody (bnab), including screening memory b cell cultures from a donor pbmc sample for neutralization activity against a plurality of hiv-1 species, cloning a memory b cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory b cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the env proteins in native or monomeric form, as well as to inhibit infection of hiv-1 species from a plurality of clades.
The Scripps Research Institute
Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
The present invention is based on a novel, alternatively spliced human isoform of md-2 (md-2s). In addition, the present invention relates to modified md-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine.
Cedars-sinai Medical Center
Interleukin-10 fusion proteins and uses thereof
The present invention generally relates to fusion proteins of antibodies and interleukin-10 (il-10). More particularly, the invention concerns fusion proteins of antibodies and mutant il-10 that exhibit improved properties for use as therapeutic agents, e.g.
Hoffmann-la Roche Inc.
A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an fc receptor binding portion comprising two immunoglobulin g heavy chain constant regions; wherein each immunoglobulin g heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin g heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject.. .
Liverpool School Of Tropical Medicine
Artificial forisome body with seo-f fusion proteins, plant or yeast cells comprising vectors which code for these proteins, as well as vectors which code for seo-f fusion proteins
The artificial forisome body of the invention is useful for protein-chemistry purposes, particularly for providing immobilized enzymes, antibodies, antigens, as well as such proteins or peptides that can be immobilized on a substrate due to their affinity reaction with a substrate-bound biological or biochemically produced material.. .
Methods for modulating tal specificity
Methods for improving or modulating targeting specificity of tale proteins by introducing alternative rvds into their modular nucleic acid binding domains. Polynucleotides encoding tale proteins having alternative targeting specificity towards a nucleic acid target sequence.
Viral fusion protein treatment for ccr8 mediated diseases
Compositions, methods, and kits are provided for treating ccr8 mediated diseases with applicability to atopic dermatitis and potential applicability to asthma, prurigo nodularis, nummular dermatitis, neurodeimatitis, and lichen simplex chronicus and some lymphomas, multiple sclerosis, acquired immunodeficiency disease, peritoneal adhesions, kaposi's sarcoma and atherogenesis—the expression of all of which, at least in part, is mediated by cells expressing the chemokine receptor ccr8. The compositions include proteins and fusion proteins from molluscum contagiosum virus (mcv) or variants, analogs and derivatives thereof which exhibit inhibitory activity.
Peptides for the binding of nucleotide targets
A method of regulating expression of a gene in a cell is described, comprising the step of introducing into the cell a recombinant polypeptide comprising a ppr rna-binding domain which itself comprises at least a pair of ppr rna base-binding motifs. The ppr rna base-binding motifs of the ppr rna-binding domain are operably capable of binding the target rna molecule with a target rna sequence.
The State Board Of Higher Education On Behalf Of The University Of Oregon
Preparation and/or purification of oligonucleotide conjugates
Methods, systems and/or kits for the preparation, purification and isolation of oligonucleotide conjugates, comprising conjugation of modified antibodies or proteins with at least one modified oligonucleotide at greater than 80% efficiency to form oligonucleotide conjugates and isolating the oligonucleotide conjugates from the conjugation solution by binding the conjugates to an immobilized binder, wherein the binder may be a metal ion or an antibody.. .
Method for preparation of site-specific protein conjugates
The invention is directed to a single-step method for rapidly and efficiently preparing protein-polymer conjugates, including an insulin-polymer conjugate. According to the method of the present invention, a protein and hydrophilic polymer are contacted in the presence of at least one organic solvent and at least one metal chelator, under conditions that promote the formation of a conjugate of the protein and polymer.
Conjugated proteins and peptides
Either z1 represents a protein or a peptide linked to cr2 via a nucleophilic moiety, and z2 represents a molecule linked to cr2 via a nucleophilic moiety, or z1 and z2 together represent a single group derived from a protein or peptide linked to cr2 via two nucleophilic moieties.. .
Drug delivery composition comprising proteins and biodegradable polyesteramides
The present invention relates to a drug delivery composition comprising proteins and biodegradable polymers. The present invention further relates to a drug delivery system for controlled and long term release of proteins into a biological environment.
Dsm Ip Assets B.v.
Stabilizing alkylglycoside compositions and methods thereof
The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (pth) or pth analogs, amylin, a monoclonal antibody, insulin, peptide t or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (grp) proteins, epidermal growth factor or analog thereof.. .
Aegis Therapeutics, Llc
Cellular vaccine and inducing an immune response in a subject
The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd
Mva vaccine for delivery of a ul128 complex and preventing cmv infection
In one embodiment, an expression system for expressing a ul128 complex is provided herein. The expression system may include a bacterial artificial chromosome (bac) construct, wherein the bac construct comprises a viral vector inserted with a set of dna sequences that encode a ul128 complex.
The Regents Of The University Of California
Immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to neisseria orf2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by neisseria meningitidis serogroup b.. .
Wyeth Holdings Llc
Bacterial live vector vaccines expressing chromosomally-integrated foreign antigens
Bacterial live vector vaccines represent a vaccine development strategy that offers exceptional flexibility. In the present invention, genes encoding protective antigens of unrelated bacterial, viral, parasitic, or fungal pathogens are expressed in an attenuated bacterial vaccine strain that delivers these foreign antigens to the immune system, thereby eliciting relevant immune responses.
University Of Maryland, Baltimore
Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
Described herein are variant, recombinant β-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type β-glucocerebrosidase. Also provided herein are variant, recombinant β-glucocerebrosidase proteins characterized as retaining more catalytic activity relative to recombinant wild-type β-glucocerebrosidase.
Amicus Therapeutics, Inc.
Expandable amnion membrane for treating non-healing wounds
The present disclosure generally pertains to methods of treating non-healing wounds. Specifically, the method includes injecting amnion fluid derived cells along the periphery of the wound.
Nutech Medical, Inc.
Sweetness enhancers, compositions thereof, and methods for use
Disclosed herein are sweetener compositions comprising at least one sweetener and at least one sweetness enhancer chosen from terpenes (such as sesquiterpenes, diterpenes, and triterpenes), flavonoids, amino acids, proteins, polyols, other known natural sweeteners (such as cinnamaldehydes, selligueians, hematoxylins), secodammarane glycosides, and analogues thereof, wherein the at least one sweetness enhancer is present in the composition in an amount at or below the sweetness detection threshold level of the sweetness ehancer, and the at least one sweetener and the at least one sweetness enhancer are different. Also disclosed herein are methods for enhancing sweetness of a composition, comprising combining at least one sweetener and at least one sweetness enhancer chosen from terpenes (such as sesquiterpenes, diterpenes, and triterpenes), flavonoids, amino acids, proteins, polyols, other known natural sweeteners (such as cinnamaldehydes, selligueians, hematoxylins), secodammarane glycosides, and analogues thereof, wherein the at least one sweetness enhancer is present in the composition in an amount at or below the sweetness detection threshold level of the at least one sweetness enhancer, and the at least one sweetener and the at least one sweetness enhancer are different..
The Coca-cola Company